Central Serous Retinopathy: Causes, Symptoms, and Treatment
Understanding Central Serous Retinopathy
The retina lines the back of the eye and converts light into signals the brain uses to create images. Beneath the retina sits a thin layer of cells called the retinal pigment epithelium (RPE). The RPE acts as a barrier between the retina and the choroid, a layer of blood vessels that supplies nutrients to the outer retina.
In CSC, this barrier breaks down. One or more small defects develop in the RPE, allowing fluid from the choroid to leak through and collect under the retina. This creates a localized serous detachment, meaning a pocket of clear fluid lifts the retina away from its normal position. When this fluid accumulates under the macula, central vision becomes blurry or distorted.
The exact cause of CSC is not fully understood. Researchers believe the condition begins with dysfunction in the choroid. This leads to increased pressure or permeability in the blood vessels beneath the RPE. This abnormal choroidal activity pushes fluid through weak points in the RPE barrier.
Corticosteroid exposure is one of the strongest known triggers. Corticosteroids are found in many common medications, including allergy nasal sprays, anti-inflammatory skin creams, oral medications for autoimmune conditions, and joint injections. Even over-the-counter products containing corticosteroids may contribute to CSC in susceptible individuals.
Most cases of CSC are classified as acute. Acute CSC typically resolves within three months without treatment, and vision often returns to near-normal levels. Chronic CSC is diagnosed when fluid persists for longer than three to four months or when there are widespread changes in the RPE. Chronic CSC carries a higher risk of lasting vision changes because prolonged fluid exposure can damage the photoreceptor cells in the retina.
Who Is Affected and Risk Factors
CSC primarily affects adults between the ages of 20 and 55. A large case-control study of 35,492 patients diagnosed with CSC between 2007 and 2015 found that the mean age at diagnosis was 49.1 years, and 69.2% of patients were male (Kitzmann et al., JAMA Ophthalmology, 2019). A population-based survey from Minnesota reported an annual incidence of 9.9 per 100,000 in men compared with 1.7 per 100,000 in women (Kitzmann et al., Ophthalmology, 2008).
Use of corticosteroids in any form is a well-established risk factor. This includes oral steroids, inhaled steroids for asthma, topical steroid creams, steroid nasal sprays, and steroid injections into joints or the spine. In the same large case-control study, patients with CSC were more likely to have received steroids in the prior year (odds ratio 1.14, 95% CI 1.09 to 1.19) (Kitzmann et al., JAMA Ophthalmology, 2019). Patients with Cushing syndrome also had an elevated risk (odds ratio 2.19) (Kitzmann et al., JAMA Ophthalmology, 2019).
Emotional stress has long been associated with CSC. Researchers have suggested a relationship between CSC and type A personality traits, which include competitiveness, urgency, and high levels of drive. The body may produce higher levels of natural corticosteroids (cortisol) during periods of stress. This may trigger CSC in people who are predisposed to the condition.
Several other factors may increase the risk of developing CSC. These include:
- Use of phosphodiesterase-5 inhibitor medications, such as those used to treat erectile dysfunction
- Use of medications for autoimmune diseases
- Diabetes mellitus (odds ratio 1.44) (Kitzmann et al., JAMA Ophthalmology, 2019)
- A family history of CSC, with about half of diagnosed patients having at least one relative with findings on retinal examination
Signs and Symptoms
The most common symptom of CSC is blurry central vision, usually in one eye. Many patients notice that straight lines appear wavy or bent, a symptom called metamorphopsia. Objects may appear smaller than normal in the affected eye, which is known as micropsia. Some patients also develop a mild shift toward farsightedness in the affected eye.
Some people with CSC notice a dim or dark spot in the center of their vision, called a central scotoma. Colors may appear washed out or duller in the affected eye compared to the other. These changes can make reading, driving, and recognizing faces more difficult.
CSC does not produce noticeable symptoms in every case. When fluid accumulates outside the macula, the patient may not experience any vision changes at all. A retina specialist may discover these cases during a routine eye examination. Even though vision seems unaffected, long-term fluid accumulation outside the macula can still cause damage over time. Careful examination often reveals some degree of involvement in the fellow eye as well.
Diagnosis and Testing
A retina specialist will begin by dilating the pupils and examining the back of the eye. During this examination, a dome-shaped area of fluid beneath the retina may be visible. The specialist will also look for changes in the RPE, such as pigment clumping or small pigment epithelial detachments.
Optical coherence tomography (OCT) is a noninvasive imaging test that creates detailed cross-sectional pictures of the retina. OCT can clearly show the pocket of fluid under the retina and measure its size. This test is essential for confirming the diagnosis, monitoring fluid over time, and determining whether the condition is responding to treatment.
Fluorescein angiography involves injecting a yellow dye into a vein in the arm and taking photographs as the dye passes through the retinal and choroidal blood vessels. In CSC, this test often reveals one or more focal points where dye leaks through the RPE. The classic appearance is an expanding dot of dye, sometimes described as a smokestack or inkblot pattern. This test helps locate the exact source of leakage.
Indocyanine green (ICG) angiography uses a different dye that is better at imaging the choroidal blood vessels beneath the RPE. This test can reveal areas of choroidal congestion and hyperpermeability not visible on fluorescein angiography. ICG angiography is particularly useful for evaluating chronic or recurrent CSC and for planning photodynamic therapy.
Treatment Options
Because most acute cases of CSC resolve within three months without treatment, many retina specialists initially recommend careful observation. During this period, patients should work with their prescribing physicians to discontinue any corticosteroid medications if it is safe to do so. It is important not to stop high-dose steroid medications suddenly, as this can cause serious medical problems. Stress management techniques may also be beneficial.
Photodynamic therapy (PDT) is one of the most effective treatments for chronic CSC. During PDT, a light-sensitive drug called verteporfin is injected into a vein in the arm. The drug travels through the bloodstream to the choroidal blood vessels in the eye. A retina specialist then shines a special low-energy laser on the area of leakage. The laser activates the verteporfin, which helps seal the abnormal leakage points without causing significant damage to the overlying retina.
Current evidence supports the use of half-dose or half-fluence verteporfin PDT as the preferred approach. This reduced-intensity protocol lowers the risk of side effects while remaining effective at reducing choroidal hyperpermeability (AAO, Retina/Vitreous PPP, 2019).
Mineralocorticoid receptor antagonists (MRAs) have become an increasingly popular treatment option for chronic and recurrent CSC. Eplerenone, a selective aldosterone-receptor antagonist originally approved for high blood pressure, has shown promise in small clinical studies. Patients treated with eplerenone at doses of 25 to 50 milligrams daily demonstrated improved visual acuity and reduced central macular thickness.
Although robust large-scale evidence is still developing, MRAs such as eplerenone may be suitable as a first-line, noninvasive treatment. They may benefit patients who prefer to avoid more invasive options or who are not good candidates for laser-based treatments. A retina specialist will monitor potassium levels and kidney function during treatment.
In some cases, a retina specialist may use focal thermal laser photocoagulation to seal a specific point of leakage identified on fluorescein angiography. This approach is generally reserved for leakage points located away from the center of the macula, because laser treatment can create a small lasting blind spot. Thermal laser is less commonly used today because photodynamic therapy offers similar effectiveness with fewer risks to central vision.
Anti-VEGF medications block vascular endothelial growth factor, a protein that drives abnormal blood vessel growth and leakage. These include Lucentis (ranibizumab) and Avastin (bevacizumab), which is FDA-approved for cancer but used off-label for eye conditions. In a prospective study, patients with chronic CSC treated with ranibizumab showed faster resolution of fluid compared to a placebo group (Kim et al., Retina, 2014). However, research on anti-VEGF therapy for CSC without choroidal neovascularization (abnormal new blood vessel growth) has shown mixed results. Anti-VEGF injections are more clearly beneficial when CSC is complicated by choroidal neovascularization.
What to Expect
Most people with a first episode of acute CSC experience significant improvement in vision within one to three months as the fluid gradually absorbs on its own. Many patients recover to 20/20 or near-normal vision. However, some patients notice subtle lingering differences between the two eyes. These may include slight changes in color perception, contrast sensitivity, or mild distortion, even after the fluid has completely resolved.
Recurrence is common with CSC. Up to half of untreated cases may experience a return of symptoms at some point (StatPearls, NCBI, 2024). Recurrences can happen months or years after the initial episode and may affect the same or the opposite eye. Patients who have had CSC should be aware of the symptoms and seek prompt evaluation if blurry or distorted vision returns.
Chronic CSC carries a less favorable prognosis than acute CSC. Prolonged or repeated episodes of fluid under the retina can lead to progressive damage to the photoreceptor cells and RPE. Over time, this may result in lasting central vision loss, reduced contrast sensitivity, and difficulty with tasks requiring fine detail. Early treatment of chronic CSC is important to minimize the risk of irreversible changes.
Living With Central Serous Retinopathy
Patients with CSC can take several steps to reduce the risk of recurrence. The most important measure is avoiding corticosteroid medications whenever possible. This includes not only prescription steroids but also over-the-counter nasal sprays and skin creams containing corticosteroids. Patients should inform all of their healthcare providers about their CSC history so that steroid-free alternatives can be considered.
Because stress may play a role in triggering CSC, many retina specialists encourage patients to incorporate stress management into their daily routines. Regular physical activity, adequate sleep, mindfulness practices, and reducing work-related pressure may all be helpful. While there is no certainty that stress reduction will prevent recurrence, it supports overall health and may lower cortisol levels.
Patients who have had CSC can monitor their vision at home using an Amsler grid, a simple chart with a pattern of straight lines. By covering one eye at a time and looking at the center dot, patients can check for new areas of distortion or blurriness. Any new changes should be reported to a retina specialist promptly. Regular follow-up examinations, even during periods of remission, help ensure that any recurrence or progression is detected early.
When to See a Retina Specialist
Anyone who experiences new blurry or distorted vision in one eye should schedule an evaluation with a retina specialist. This is especially important for individuals previously diagnosed with CSC, those who use corticosteroid medications, and men between the ages of 20 and 55. Early evaluation can help distinguish CSC from other conditions that may require different treatment.
Certain symptoms should prompt immediate evaluation. See a retina specialist or go to the emergency room right away if you experience:
- A sudden increase in floaters (spots or strands drifting across your vision)
- Flashes of light in your peripheral vision
- A shadow or curtain spreading across part of your visual field
- Sudden loss of vision in one eye
These symptoms may indicate a retinal detachment or another serious condition that requires urgent treatment. While CSC itself is not typically an emergency, these warning signs must not be ignored.
Questions and Answers
Most people with a single acute episode of CSC recover good vision once the fluid resolves. However, chronic or frequently recurring CSC can lead to lasting damage to the photoreceptor cells and RPE. Over time, this damage may cause long-term reductions in visual acuity, contrast sensitivity, and color perception. Seeking treatment for chronic CSC can help reduce the risk of irreversible changes.
Even low-dose corticosteroids found in over-the-counter products can potentially trigger or worsen CSC in susceptible individuals. If you have a history of CSC, discuss all medications, including over-the-counter products, with your retina specialist and other healthcare providers. There are often steroid-free alternatives available for allergies and skin conditions that may be safer for people with a history of CSC.
A retina specialist typically monitors acute CSC for about three months to allow the fluid to resolve on its own. If symptoms persist beyond that timeframe, or if you have had previous episodes, treatment may be recommended sooner. The timing of treatment depends on several factors, including the location and amount of fluid, the duration of symptoms, and whether there are signs of chronic changes. Your retina specialist will create a plan based on your specific situation.
CSC most commonly causes noticeable symptoms in one eye at a time. However, careful examination by a retina specialist often reveals subtle changes in the fellow eye as well. In some cases, CSC can affect both eyes at different times. Having CSC in one eye increases awareness that the other eye may develop the condition in the future, which is another reason regular follow-up is important.
There is no strong scientific evidence that any specific dietary supplement can treat or prevent CSC. Unlike age-related macular degeneration, where certain vitamin formulations have been studied, CSC does not have established nutritional guidelines. A balanced diet that supports overall cardiovascular health may be beneficial. Patients should not rely on supplements as a substitute for medical evaluation and treatment by a retina specialist.